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Abstract Sweet syndrome is a rare neutrophilic dermatosis consisting in the onset of high 
fever, neutrophilia, and typical painful skin lesions including erythematous papules, nodules, 
and plaques on the face, trunk, and extremities, with a bilateral and asymmetrical pattern. 
Sweet syndrome is classiied as idiopathic, predominating in women; malignancy-associated, 
mainly with hematological cancer, and drug-induced.
The diagnosis is based on clinical history and skin manifestations, being conirmed by a comple-
te blood count showing neutrophilic leukocytosis, and speciic indings in the skin biopsy.
We report the case of a 68 year-old man with a 10-year evolution of dermatomyositis complica-
ted by lung ibrosis, followed 8 years later by non-Hodgkin lymphoma (NHL) accompanied by 
worsening of his ibrosis. Two years after the successful treatment of NHL the patient developed 
an acute episode of severe dyspnea, multiple skin lesions, and 95% neutrophilia. At that time 
the patient had a severe lung function impairment complicated by nosocomial pneumonia that 
led to his death, a few days after the diagnosis of Sweet syndrome was established by histo-
pathology examination.
Sweet syndrome is a rare dermatologic entity that can appear several years after diseases cha-
racterized by immune dysfunction such as dermatomyositis and NHL.
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Introduction
Sweet syndrome was irst described in 1964 by Robert Dou-
glas Sweet.1 In 1986 Su and Liu postulated the criteria for its 
diagnosis.2 There is no racial predilection, and it is more fre-
quent in women (4:1).3-5
The disease consists of high fever, neutrophilia, and typi-
cal painful skin lesions including erythematous papules, no-
dules, and plaques on the face, trunk, and extremities, with 
a bilateral and asymmetrical pattern.6,7
Sweet syndrome is classiied as: a) idiopathic, which pre-
dominantly affects women between 30 and 50 years of 
age;6,8 b) malignancy-associated, which appears to affect 
men and women equally; in about 20% of the cases the syn-
drome is associated with a malignancy, most often acute 
leukemia;9,10 c) drug-induced, which may occur as a reaction 
to a medication, most frequently to granulocyte colony-sti-
mulating factor (G-SCF).11-14 
The diagnosis is confirmed by a complete blood count 
(CBC) showing leukocytosis with a predominance of neutro-
phils, and a skin biopsy demonstrating edema of the papi-
llary dermis and a dense inlammatory leukocyte iniltrate 
in the lower dermis.5,6,15 
The treatment includes prednisolone, or potassium iodi-
de, colchicine, and Lugol’s solution.5,6,16 Usually recovery is 
complete with no recurrence. 
Case report
The patient, a 68-year-old man, irst showed symptoms in 
April 2000 with minimum effort dyspnea, accompanied by 
constitutional symptoms and generalized myalgias with 
weakness and muscular fatigue. At the time the CBC was 
normal, but blood chemistry results showed diverse abnor-
malities including albumin 1.7 g/dl, globulin 4.1 g/dl, lactic 
dehydrogenase 688 U/l, creatine kinase 7,402 U/l, alanine 
aminotransferase 283 U/l and aspartate aminotransfera- 
se 521 U/l. Chest X-rays showed a bibasal reticular iniltrate 
(Fig. 1, panel A). Computed tomography (CT) imaging docu-
mented interstitial ibrosis in the descamative phase. Spi-
rometry reported a mild to moderate restrictive process. 
Electromyography of the 4 extremities reported myopathic 
inlammatory pattern. A muscle biopsy of the quadriceps 
was normal. Diagnosis of dermatomyositis with secondary 
lung ibrosis was established and treatment with prednisone 
and methotrexate was started. 
In 2008, physical examination revealed a 12 x 6 cm mass 
of coalescent adenopathies, irm, nontender, ixed to deep 
planes in the parotid gland, as well as cervical, retroauricu-
lar, bilateral axillary and inguinal lymphadenopathies; in 
addition, the patient presented B symptoms; there was no 
visceral enlargement. An excisional biopsy of the axillary 
and left groin lymph nodes was carried out, leading to the 
diagnosis of high-grade diffuse large cell non-Hodgkin lym-
phoma (NHL) with a B immunophenotype. Bone marrow 
aspirate showed a moderate granulocytic hyperplasia (Fig. 
1, panel B). Treatment included rituximab, cyclophosphami-
de, doxorubicin, and vincristine. 
The patient had no major complications until November 
2010, when he was admitted to the emergency room after 3 
weeks of experiencing malaise, fatigue, and weakness, 
coupled with the presence of disseminated macular derma-
tosis, which prompted a consultation to a dermatologist; at 
that time the patient had painful erythematous papules 
both over the dorsum of his forearm and face. The lesions 
rapidly progressed to become nodules and a few of them 
coalesced forming plaques (Fig. 1, panel C). A skin punch 
biopsy performed on a left cheek lesion, demonstrated pro-
minent iniltration of leucocytes into the dermis, consistent 
with the diagnosis of sweet syndrome. (Fig. 1, panels D and 
E). A CBC reported 10.9 x 109/l WBC, and neutrophilia of 
10.3 x 109/l, representing 94.7% of total leukocytes.
During his stay at the hospital, the patient developed no-
socomial pneumonia that progressed to respiratory failure, 
and broad spectrum antibiotics were started; a CT scan 
of the chest showed diffuse bilateral iniltrates, as well as 
Figure 1 A) The chest X-rays from 2008 (left) show a bibasal 
reticular iniltrate; 2 years later on the last X-rays (right) diffu-
se bilateral iniltrates as well as signiicant progression of pul-
monary ibrosis were documented. B) Bone marrow aspirate; 
moderate granulocytic hyperplasia. C) Sweet syndrome. Six-
tyeight male patient with disseminated dermatosis to the face, 
predominating on the right supraorbital area and near the naso-
genian ipsilateral furrow, characterized by ulcerated plaques 
illed with necrotic central tissue and partly covered with crust, 
surrounded by eritema, giving a targetoid appearance. D) Mi-
croscopic low-power magniication view of a hematoxylin and 
eosin-stained skin punch biopsy performed on a left cheek le-
sion, demonstrating slight spongiosis and supericial erosions 
scattered in the epidermis, with prominent dense iniltration of 
leucocytes into the dermis. E) Microscopic high-power view de-
monstrating dense neutrophilic infiltration in the upper and 
mid-dermis and neutrophil karyorrhexis.
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signiicant progression of pulmonary ibrosis. The ventila-
tory function worsened, leading to a cardiorespiratory 
arrest and death of the patient a week after his admission 
to the hospital.
Discussion
Several theories to explain the pathogenesis of Sweet syn-
drome exist.17 3 are widely supported a type III hyper- 
sensitivity reaction, an activation of T cells by antigens or 
superantigens, and a disturbance in the function of the neu-
trophiles. An additional theory notes that inappropriate se-
cretion of interleukin 1 (IL-1) can stimulate macrophages 
and then cause a rise in the production of G-CSF, responsible 
for increasing IL-8, a chemotactic factor for neutrophils.5,6 
Confirming the knowledge about dermatomyositis in 
that 10% to 25% of the cases progress to a malignancy,18,19 
eight years after its diagnosis and successful therapy, the 
patient developed NHL that was also successfully treated 
and remained in remission. 
Our patient presented three conditions associated with 
the diagnosis of Sweet syndrome: an hematologic disorder, a 
severe infectious process, and an autoimmune disease.20 In 
this case it is dificult to establish deinitively whether the 
syndrome was associated to NHL or its therapy, as his der-
matomyositis was not completely controlled, as shown by 
progressive lung ibrosis and subsequent fatal pneumonia; 
another possibility is that both conditions acted as a trigger 
for the development of Sweet syndrome.
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